]>

IRCT201305212324N9 IRCT 2014-01-18 Vice chancellor for research, Tehran University of Medical Sciences The effect of vitamin D on severity of primary dysmenorrhea and amount of menstrual bleeding The effect of vitamin D on severity of primary dysmenorrhea and amount of menstrual bleeding compared with placebo in students living in dormitories of Tehran University of Medical Sciences: Randomized, Double-blind, clinical trial 2013-09-23 anticipated Complete https://irct.ir/trial/1964 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2-3 primary dysmenorrhea. Intervention 1: Contorol group will be received oral tablet of placebo, 2 tablets every 8 hours, 5 days before the putative beginning of their next menstrual cycle. Intervention 2: Case group will be received oral tablet of cholecalciferol (50000 IU of cholecalciferol), 2 tablets every 8 hours, 5 days before the putative beginning of their next menstrual cycle.

public Elham Ghorbali

Nosrat Eastern St, Tohid Sq

Tehran Iran (Islamic Republic of) 1419733171 +98 21 6105 4219 elhamghorbali@yahoo.com; elhamghorbali@gmail.com School of Nursing and Midwifery, Tehran University of Medical Sciences scientific Maryam Keshavarz

Midwifery dep, School of Nursing Midwifery, Iran University of Medical Sciences, Rashid Yasami St, Vanak Sq, Tehran.Iran

Tehran Iran (Islamic Republic of) +98 21 6105 4219 Keshavarz.m@iums.ac.ir; m_keshir@yahoo.com School of Nursing and Midwifery, Iran University of Medical Sciences Iran (Islamic Republic of) Iran (Islamic Republic of) Inclusion criteria: Healthy, iranian and single female students aged 18 to 25 years؛ With normal menstrual cycles (cycles lasted 21 to 35 days, mensturation lasting 3 to 7 days)؛ Experienced at least 4 consecutive painful periods in the past 6 months with the pain starting a few hours before or just after the onset of bleeding؛ No history of underlying disease cause of secondary dysmenorrhea sush as: endometriosis and adenomyosis,etc؛ Don’t do any regular exercise؛ Lack of stressful experiences within 3 months prior؛ Don’t use of oral contraceptives and hormonal drugs within 3 months prior؛ Taking no medications including calcium and vitamin D within 6 months prior؛ 25(OH)D serum level ≤ 30 ng/ml and normal serum calcium؛ Having no unusual diets (vegetarian diets, special diet)؛ Don’t use of medicines that interact with vitamin D such as: hydantoin and barbiturates,etc؛ BMI ≤ 30؛ No smoking and alcohol consumption. Exclusion criteria: Lack of menstruation؛ Married during the study؛ Use of medications including calcium and vitamin D during the study؛ Use of oral contraceptives and hormonal drugs during the study ؛Use of non-pharmacological methods of pain relief ؛Intense psychological stress during the study؛ Start exercise during the study ؛Don’t use of supplement or interventions intended ؛Occurring gastrointestinal disorders after the consumption of supplement (Including vomiting 2 hours after the consumption of supplement ؛(Unwillingness to continue research. 18 years 25 years Female N94.4 primary dysmenorrhea Placebo Treatment - Drugs Contorol group will be received oral tablet of placebo, 2 tablets every 8 hours, 5 days before the putative beginning of their next menstrual cycle. Case group will be received oral tablet of cholecalciferol (50000 IU of cholecalciferol), 2 tablets every 8 hours, 5 days before the putative beginning of their next menstrual cycle. Pain score of primary dysmenorrhea. Timepoint: Before intervention, the first cycle after intervention, the Second cycle after intervention. Method of measurement: visual analog scale (VAS). Amount of menstrual bleeding. Timepoint: Before intervention, the first cycle after intervention, the Second cycle after intervention. Method of measurement: Pictorial blood loss assessment chart. Severity of primary dysmenorrhea. Timepoint: Before intervention, the first cycle after intervention, the Second cycle after intervention. Method of measurement: Verbal multidimensional scoring system (VMS). Use of NSAIDs. Timepoint: Before intervention, the first cycle after intervention, the Second cycle after intervention. Method of measurement: Record sheet of NSAID use. no no Vice chancellor for research, Tehran University of Medical Sciences Approved 2013-09-24 Ethical commitment of Tehran University of Medical Sciences Sixth floor ,Central office, Ghods St, Keshavarz Blvd- Tehran, Iran Tehran Iran (Islamic Republic of)